Suppr超能文献

靶向细胞角鲨烯合酶(一种胆固醇生物合成所必需的酶)是一种针对丙型肝炎病毒的潜在抗病毒策略。

Targeting cellular squalene synthase, an enzyme essential for cholesterol biosynthesis, is a potential antiviral strategy against hepatitis C virus.

作者信息

Saito Kyoko, Shirasago Yoshitaka, Suzuki Tetsuro, Aizaki Hideki, Hanada Kentaro, Wakita Takaji, Nishijima Masahiro, Fukasawa Masayoshi

机构信息

Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan.

Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan Graduate School of Biological Science, Tokyo University of Science, Chiba, Japan.

出版信息

J Virol. 2015 Feb;89(4):2220-32. doi: 10.1128/JVI.03385-14. Epub 2014 Dec 3.

Abstract

UNLABELLED

Hepatitis C virus (HCV) exploits host membrane cholesterol and its metabolism for progeny virus production. Here, we examined the impact of targeting cellular squalene synthase (SQS), the first committed enzyme for cholesterol biosynthesis, on HCV production. By using the HCV JFH-1 strain and human hepatoma Huh-7.5.1-derived cells, we found that the SQS inhibitors YM-53601 and zaragozic acid A decreased viral RNA, protein, and progeny production in HCV-infected cells without affecting cell viability. Similarly, small interfering RNA (siRNA)-mediated knockdown of SQS led to significantly reduced HCV production, confirming the enzyme as an antiviral target. A metabolic labeling study demonstrated that YM-53601 suppressed the biosynthesis of cholesterol and cholesteryl esters at antiviral concentrations. Unlike YM-53601, the cholesterol esterification inhibitor Sandoz 58-035 did not exhibit an antiviral effect, suggesting that biosynthesis of cholesterol is more important than that of cholesteryl esters for HCV production. YM-53601 inhibited transient replication of a JFH-1 subgenomic replicon and entry of JFH-1 pseudoparticles, suggesting that at least suppression of viral RNA replication and entry contributes to the antiviral effect of the drug. Collectively, our findings highlight the importance of the cholesterol biosynthetic pathway in HCV production and implicate SQS as a potential target for antiviral strategies against HCV.

IMPORTANCE

Hepatitis C virus (HCV) is known to be closely associated with host cholesterol and its metabolism throughout the viral life cycle. However, the impact of targeting cholesterol biosynthetic enzymes on HCV production is not fully understood. We found that squalene synthase, the first committed enzyme for cholesterol biosynthesis, is important for HCV production, and we propose this enzyme as a potential anti-HCV target. We provide evidence that synthesis of free cholesterol is more important than that of esterified cholesterol for HCV production, highlighting a marked free cholesterol dependency of HCV production. Our findings also offer a new insight into a role of the intracellular cholesterol pool that is coupled to its biosynthesis in the HCV life cycle.

摘要

未标记

丙型肝炎病毒(HCV)利用宿主细胞膜胆固醇及其代谢来产生子代病毒。在此,我们研究了靶向细胞角鲨烯合酶(SQS)(胆固醇生物合成的首个关键酶)对HCV产生的影响。通过使用HCV JFH - 1毒株和源自人肝癌Huh - 7.5.1的细胞,我们发现SQS抑制剂YM - 53601和扎戈司亭A可降低HCV感染细胞中的病毒RNA、蛋白质及子代病毒的产生,且不影响细胞活力。同样,小干扰RNA(siRNA)介导的SQS敲低导致HCV产生显著减少,证实该酶为抗病毒靶点。一项代谢标记研究表明,YM - 53601在抗病毒浓度下可抑制胆固醇和胆固醇酯的生物合成。与YM - 53601不同,胆固醇酯化抑制剂桑多斯58 - 035未表现出抗病毒作用,这表明胆固醇的生物合成对于HCV产生比胆固醇酯的生物合成更为重要。YM - 53601抑制JFH - 1亚基因组复制子的瞬时复制以及JFH - 1假病毒颗粒的进入,这表明至少对病毒RNA复制和进入的抑制有助于该药物的抗病毒作用。总体而言,我们的研究结果突出了胆固醇生物合成途径在HCV产生中的重要性,并表明SQS作为抗HCV抗病毒策略的潜在靶点。

重要性

已知丙型肝炎病毒(HCV)在整个病毒生命周期中与宿主胆固醇及其代谢密切相关。然而,靶向胆固醇生物合成酶对HCV产生的影响尚未完全了解。我们发现角鲨烯合酶(胆固醇生物合成的首个关键酶)对HCV产生很重要,并提出该酶作为潜在的抗HCV靶点。我们提供的证据表明,游离胆固醇的合成对于HCV产生比酯化胆固醇的合成更为重要,突出了HCV产生对游离胆固醇的显著依赖性。我们的研究结果还为细胞内胆固醇池在HCV生命周期中与其生物合成相关的作用提供了新的见解。

相似文献

2
Farnesyl-diphosphate farnesyltransferase 1 regulates hepatitis C virus propagation.
FEBS Lett. 2014 May 2;588(9):1813-20. doi: 10.1016/j.febslet.2014.03.043. Epub 2014 Mar 29.
4
Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
J Hepatol. 2015 Mar;62(3):541-8. doi: 10.1016/j.jhep.2014.10.040. Epub 2014 Nov 4.
6
Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment.
Liver Int. 2010 Feb;30(2):311-8. doi: 10.1111/j.1478-3231.2009.02144.x. Epub 2009 Oct 16.
7
In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
Antiviral Res. 2013 Nov;100(2):439-45. doi: 10.1016/j.antiviral.2013.08.018. Epub 2013 Sep 5.
8
Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity.
J Hepatol. 2015 Oct;63(4):813-21. doi: 10.1016/j.jhep.2015.06.002. Epub 2015 Jun 10.
9
Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity.
Antiviral Res. 2011 Feb;89(2):136-48. doi: 10.1016/j.antiviral.2010.12.005. Epub 2010 Dec 15.
10
Suppression of hepatitis C virus replication by cyclin-dependent kinase inhibitors.
Antiviral Res. 2014 Aug;108:79-87. doi: 10.1016/j.antiviral.2014.05.011. Epub 2014 Jun 2.

引用本文的文献

4
Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model.
J Virol. 2018 Mar 28;92(8). doi: 10.1128/JVI.02258-17. Print 2018 Apr 15.
6
Statins inhibit blastocyst formation by preventing geranylgeranylation.
Mol Hum Reprod. 2016 May;22(5):350-63. doi: 10.1093/molehr/gaw011. Epub 2016 Feb 7.
7

本文引用的文献

1
Isolation and characterization of an Huh.7.5.1-derived cell clone highly permissive to hepatitis C virus.
Jpn J Infect Dis. 2015;68(2):81-8. doi: 10.7883/yoken.JJID.2014.231. Epub 2014 Nov 25.
3
Farnesyl-diphosphate farnesyltransferase 1 regulates hepatitis C virus propagation.
FEBS Lett. 2014 May 2;588(9):1813-20. doi: 10.1016/j.febslet.2014.03.043. Epub 2014 Mar 29.
4
Antiviral therapy of hepatitis C in 2014: do we need resistance testing?
Antiviral Res. 2014 May;105:64-71. doi: 10.1016/j.antiviral.2014.02.011. Epub 2014 Feb 25.
5
Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment.
J Virol. 2013 Oct;87(19):10612-27. doi: 10.1128/JVI.01370-13. Epub 2013 Jul 24.
7
Current progress in the treatment of chronic hepatitis C.
World J Gastroenterol. 2012 Nov 14;18(42):6060-9. doi: 10.3748/wjg.v18.i42.6060.
8
Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus life cycle.
Microbes Infect. 2013 Jan;15(1):45-55. doi: 10.1016/j.micinf.2012.10.003. Epub 2012 Oct 23.
9
Current and emerging antiviral treatments for hepatitis C infection.
Br J Clin Pharmacol. 2013 Apr;75(4):931-43. doi: 10.1111/j.1365-2125.2012.04419.x.
10
Lipid metabolite profiling identifies desmosterol metabolism as a new antiviral target for hepatitis C virus.
J Am Chem Soc. 2012 Apr 25;134(16):6896-9. doi: 10.1021/ja207391q. Epub 2012 Apr 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验